Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
Data Provide Proof-of-Concept for an Allogeneic Anti-CD70 CAR T Candidate in Patients with Renal Cell Carcinoma Who Received Prior Immune Checkpoint Inhibitor and VEGF-Targeting TherapySingle... | April 17, 2023
United States Allogene Allo Christine Cassiano Zachary Roberts Samera Srour University Of Texas Md Anderson Cancer Center
Source: marketscreener.com